Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose)

PURPOSE: To compare 2.0 mg ranibizumab (RBZ) injections with 0.5 mg RBZ for eyes with center-involved diabetic macular edema (DME) and a central subfield thickness (CFT) of ≥250 μm on time-domain optical coherence tomography.DesignRandomized, controlled, multicenter clinical trial

Bibliographic Details
Published in:Eye (London, England), Vol. 29, No. 12 (2015), p. 1538-44
Main Author: Do, D V
Other Involved Persons: Sepah, Y J ; Boyer, D ; Callanan, D ; Gallemore, R ; Bennett, M ; Marcus, D M ; Halperin, L ; Sadiq, M A ; Rajagopalan, N ; Campochiaro, P A ; Nguyen, Q D ; READ-3 Study Group ; Do, Diana V ; Belz, Jennifer ; Marcus, Dennis ; Foster, Allison ; Lit, Eugene ; Renslow, Scotty ; Kruger, Erik ; Yuhas, Patty ; Pollack, John ; Ciscato, Barbara ; Halperin, Larry ; Lopez, Jackie ; Bennett, Michael ; Rego, K'Marie ; Gallemore, Ron ; Chen, Lillian ; Boyer, David ; Tam, Amanda ; Callanan, David ; Lash, Sandy ; Zhang, Kang ; Crocker, Maureen ; Symons, Andrew ; Bothwell, Rebecca ; Abraham, Prema ; Green, Buffi ; Callanan, David G ; Campochiaro, Peter A ; Nguyen, Quan Dong ; Conway, Brian P ; Wilson, David J ; Sepah, Yasir Jamal ; Sadiq, Mohammad Ali ; Hanout, Mostafa ; Sarwar, Salman ; Maya, Jose ; Rajagopalan, Nithya ; Agarwal, Aniruddha ; Soliman, Mohamed K ; Greer, Lisa
Format: electronic Article
Language:English
ISSN:1476-5454
Item Description:Date Completed 12.07.2016
Date Revised 13.11.2018
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description:Online-Ressource
DOI:10.1038/eye.2015.142
Subjects:
QR Code: Show QR Code